Sfoglia per AUTORE
BANZI M
Collezione AO Cuneo

  

Items : 2

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. in British journal of cancer / Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

2017
ASL Biella
AO Cuneo

Cremolini C; Falcone A; Boni L; Tomcikova D; Paris M; Bonetti A; Martignetti A; Dargenio F; Miraglio E; Amoroso D; Banzi MC; Borelli B; Chiara S; Loupakis F; Masi G; Allegrini G; Barbara C; Salvatore L; Antonuzzo L; Marmorino F;

Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO) in Journal of Clinical Oncology

2013
AO Cuneo

Masi G; Loupakis F; Salvatore L; Cremolini C; Fornaro L; Schirripa M; Granetto C; Miraglio E; Di Costanzo F; Antonuzzo L; Marcucci L; Barbara C; Boni C; Banzi M; Chiara S; Garbarino D; Valsuani C; Bonetti A; Boni L; Falcone A;